Multiple Sclerosis

Among 6 sphingosine-1-phosphate (S1P) receptor modulators evaluated for use in patients with multiple sclerosis (MS), a new meta-analysis shows amiselimod had the highest efficacy.

Advocates for patients with progressive multiple sclerosis (MS) want changes in study designs on emerging therapies to speed development and better align with the needs of researchers and patients.

The current guidance emphasizes that the mRNA-based Pfizer/BioNTech and Moderna vaccines are safe for people with multiple sclerosis (MS) taking disease modifying therapies (DMTs).

Timing of relapses in multiple sclerosis is one of several interactions among aging, the trajectory of progressive disease, and worsening disability, according to Burcu Zeydan, MD, assistant professor of neurology, assistant professor of radiology, at the Mayo Clinic.

Compared with patients with Parkinson disease, rheumatoid arthritis, or epilepsy, those with multiple sclerosis exhibited higher rates of medication adherence throughout the first year of treatment.

Investigators observed that some patients had improvements in their multiple sclerosis (MS) severity with increased sun exposure, whereas photosensitive individuals and those taking certain medications did not see the same effects.

Peer-led education was found to have a greater impact on multiple sclerosis (MS) health literacy than lecture-based education, a recent study from Iran demonstrated.

The findings suggest that this new categorization of cognitive deficits in multiple sclerosis may support clinicians in treatment choices and help tailor cognitive rehabilitation strategies, the authors said.

Periodic review of treatment safety and monitoring are necessary as medical centers increasingly use newer disease-modifying therapies earlier in the course of multiple sclerosis.

The coronavirus disease 2019 (COVID-19) pandemic dominated headlines for much of 2020, and most of the top 5 multiple sclerosis articles of this year discussed the effects of COVID-19 on patients with this disease. Others touched on physician and patient assessments of relapse and potential new treatments for neural damage.

Researchers analyzed the available evidence on the treatment’s efficacy and safety profile from the RADIANCE and SUNBEAM trials.

As a neurodegenerative disease, secondary progressive multiple sclerosis (SPMS) may lead to a degradation of cognition skills as the disease progresses.

A new study indicates that an analysis of serum and cerebrospinal fluid cytokine levels can identify multiple sclerosis and its forms.

The German multiple sclerosis (MS) study found differences by gender for some costs, but the overall economic burden of the disease was about the same.

A recent review examines the prevalence of headache among patients with multiple sclerosis, particularly migraine.

The Dutch study sought to add to what is known about the cost-effectiveness of shared decision-making in multiple sclerosis.

Multiple factors come into play when providers and patients discuss a disease-modifying therapy for multiple sclerosis (MS), explains Patricia K. Coyle, MD, of Stony Brook University Neurosciences Institute.

Prior research has found increased colon and breast cancer in patients with multiple sclerosis (MS), but that was not borne out in this current study.

Patients with multiple sclerosis (MS) may not have an increased risk of contracting coronavirus disease 2019 (COVID-19), explained John Corboy, MD, of the University of Colorado Denver, School of Medicine.

The shift to treat patients with pediatric-onset multiple sclerosis (POMS) who are treated earlier with a wider variety of medications has led to better outcomes, according to a recent study.

Ruth Ann Marrie, MD, PhD, director of the Multiple Sclerosis Clinic at the University of Manitoba, discusses how comorbidities affect treatment and options for patients with multiple sclerosis (MS).

Which types of comorbidities have the greatest impact on direct and indirect costs of multiple sclerosis (MS) over time?

Patricia K. Coyle, MD, of Stony Brook University Neurosciences Institute, explains how studies are trying to answer a debate about 2 approaches to treat multiple sclerosis (MS).

Ruth Ann Marrie, MD, PhD, director of the Multiple Sclerosis Clinic at the University of Manitoba, speaks about the overall prevalence of comorbidities in patients with multiple sclerosis (MS).

The study sought to determine if 2 specific types of adverse childhood experiences, abuse and neglect, are linked with multiple sclerosis (MS) and other immune-mediated inflammatory diseases.

The procedure might work best in patients who have had multiple sclerosis (MS) for less than 10 years, the report said.

Quality of life for patients with multiple sclerosis (MS) could be better when they are off medication because they will not have adverse effects related to those medications, said John Corboy, MD, professor of neurology, University of Colorado Denver, School of Medicine.

Two abstracts presented at a recent multiple sclerosis meeting examined depression in pregnancy and pregnancy outcomes in ozanimod trials.

The researchers noted that although it is known that pregnancy is linked to reduced MS activity, the effect of pregnancy before MS diagnosis is unclear.

Differences in clinical and demographic characteristics between men and women with multiple sclerosis (MS) are more prevalent regarding disease course than they are when stratifying by sex.